Envista (NYSE:NVST) Price Target Raised to $22.00

Envista (NYSE:NVST) had its target price increased by equities research analysts at UBS Group from $18.00 to $22.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price target suggests a potential upside of 9.89% from the stock’s current price.

NVST has been the subject of several other research reports. Piper Sandler reduced their price target on shares of Envista from $18.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. Bank of America reduced their price target on shares of Envista from $26.00 to $23.00 and set a “buy” rating for the company in a report on Tuesday, April 29th. Baird R W upgraded shares of Envista from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 27th. Evercore ISI upped their price target on shares of Envista from $19.00 to $23.00 and gave the company an “outperform” rating in a report on Wednesday, July 9th. Finally, Morgan Stanley set a $16.00 price target on shares of Envista in a report on Tuesday, April 15th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Envista presently has a consensus rating of “Hold” and a consensus price target of $20.54.

Envista Stock Down 1.4%

Shares of NYSE NVST opened at $20.02 on Tuesday. The stock has a market cap of $3.39 billion, a P/E ratio of -3.07, a P/E/G ratio of 1.28 and a beta of 1.00. The firm has a 50 day moving average price of $19.29 and a 200 day moving average price of $18.60. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.82 and a current ratio of 2.12. Envista has a 52-week low of $14.22 and a 52-week high of $23.00.

Envista (NYSE:NVST) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.04. The firm had revenue of $616.90 million during the quarter, compared to analysts’ expectations of $608.17 million. Envista had a negative net margin of 44.90% and a positive return on equity of 4.07%. The business’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.26 earnings per share. Analysts expect that Envista will post 1 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. UMB Bank n.a. raised its position in Envista by 214.4% during the first quarter. UMB Bank n.a. now owns 2,094 shares of the company’s stock worth $36,000 after acquiring an additional 1,428 shares in the last quarter. Parallel Advisors LLC raised its position in Envista by 100.1% during the second quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock worth $55,000 after acquiring an additional 1,397 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp bought a new stake in Envista during the fourth quarter worth $86,000. Palouse Capital Management Inc. raised its position in Envista by 14.4% during the first quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company’s stock worth $163,000 after acquiring an additional 1,186 shares in the last quarter. Finally, FourThought Financial Partners LLC bought a new stake in Envista during the first quarter worth $180,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.